Rain Therapeutics is a operator of a clinical stage biotechnology company.
Rain Therapeutics develops targeted therapies for patients with cancer. We begin by identifing cancers with a single, and clear, oncogenic driver and evaluating sub-populations of cancer populations with an unmet need, where standards of care are ineffective. Our global scientific and thought-leader network drives our asset and technology identification to match these cancers with small molecule therapeutics targeted at treating specific cancer mutations.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 21, 2018 | Series A | $18.36M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
University of Auckland Inventors Fund | — | Series A |